6 min read
1 min read
Certus PV, a Veristat Company experts recently lead an Xtalks webinar - View it On-Demand Now
Since the MHPD guidance Reporting Adverse Reactions to Marketed Health Products was last published in 2018, Health Canada has identified several elements of the guidance that require updates to further clarify adverse reaction reporting requirements. Consequently, draft guidance was issued in January 2021 for consultation. This consultation is looking for feedback on the proposed updates to ensure they are clear and relevant and support understanding of the regulatory reporting requirements for the industry.
Join our experts to learn about the changes and implications of the updated MHPD draft guidance.
View the Webinar On-Demand Now
Click on the image and the video and presentation files will open directly in a new window:
 |
Open the Webinar ReplayVideo Now |
 |
Open thePresentation Now |
Meet the Speakers
Anna Bussel, PV & MI Manager, Certus PV
Anna Bussel is a Pharmacovigilance and Medical Information Manager at Certus PV, a Veristat Company. She holds a Master’s Degree in Pharmacy and has over 10 years of experience in Pharmacovigilance, Regulatory Affairs and Product Quality from Europe, Canada, and the US. Anna’s pharmacovigilance expertise includes medical assessments of Individual Case Safety Reports, aggregate report preparation, screening and processing of the Canada Vigilance Adverse Reaction Online Database, literature screening, compliance management, and GVP auditing.
Elisabete Rego, PV & MI Manager, Certus PV
Elisabete Rego is a Pharmacovigilance and Medical Information Manager at Certus PV, a Veristat Company. She holds a Master’s degree in Biomedical Sciences. Elisabete is an accomplished bilingual Pharmacovigilance and Medical Information professional with over 6 years of experience in the industry combined with extensive scientific knowledge in several therapeutic areas. Elisabete leads complex Pharmacovigilance and Medical Information projects while ensuring regulatory and contractual compliance.
- Learn more about our Clinical Trial Safety Management - Pharmacovigilance services
- Read about Veristat's expanded Pharmacovigilance and Safety Services with Acquisition of Certus PV